Clinical Trial Details
| Trial ID: | L0971 |
| Source ID: | NCT00819338 |
| Associated Drug: | Efamax |
| Title: | The Effect of n-3 Polyunsaturated Fatty Acid Supplementation in Patients With Non-alcoholic Fatty Liver Disease |
| Acronym: | -- |
| Status: | Not recruiting |
| Study Results: | No Results Available |
| Results: | -- |
| Conditions: | Non-alcoholic Fatty Liver Disease |
| Interventions: | Dietary Supplement: Efamax |
| Outcome Measures: | Reduction of intrahepatic fat content as determined by magnetic resonance spectroscopySerum liver function tests, lipids, free fatty acids;Insulin resistance as assessed by HOMA-IR and Adipose Tissue Insulin Resistance Index;Liver saturated, monounsaturated and polyunsaturated fatty acid indexes as assessed by MR spectroscopy;Visceral obesity as quantified by MRI, and the adipose derived serum leptin and adiponectin;Primary assessment of the fibrotic and inflammatory status of the liver with serum TGF beta, TNF a, IL-6, IL-8, IL-8, IL-10;Further informative cytokine analyses: GM-CSF, IFN-G, IL-1B, IL-1RA, IL-2, IL-4, IL-5, MCP1;Compliance assessed by serum phospholipid fatty acids |
| Sponsor/Collaborators: | University of Nottingham |
| Gender: | All |
| Age: | 18 Yearsnan |
| Phases: | Phase 2 |
| Enrollment: | 58 |
| Study Type: | Interventional |
| Study Designs: | Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment |
| Start Date: | 08/01/2009 |
| Completion Date: | -- |
| Results First Posted: | -- |
| Last Update Posted: | 19 February 2015 |
| Locations: | United Kingdom |
| URL: | http://clinicaltrials.gov/show/NCT00819338 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D118 | Efamax | Miscellany | -- | -- | Antimycobacterial drug | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |